Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467977 | 0.90 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL2652404 | 0.89 | ALDH1A1 (0.46) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL4465738 | 0.79 | KMT2A (0.40) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL20733275 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL22662833 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL1305595 | 0.75 | KMT2A (0.53) | ALDH1A1KMT2ALMNA | |
| SCHEMBL1446504 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL4468451 | 0.72 | KMT2A (0.46) | SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL17599243 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL12385867 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTALDH1A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | claimed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | claimed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | claimed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | claimed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | SMN1; SMN2 3892/4885MAPT 4505/4885ALDH1A1 918/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | SMN1; SMN2 3803/4885MAPT 3067/4885ALDH1A1 1738/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | SMN1; SMN2 3720/4885MAPT 1936/4885ALDH1A1 2848/4885 |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | SMN1; SMN2 3648/4885MAPT 1881/4885ALDH1A1 2793/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | SMN1; SMN2 3648/4885MAPT 1881/4885ALDH1A1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.